Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
Hematology/Oncology Clinics of North America|August 7, 2013
Treating the HER2 pathway in early and advanced breast cancerMark D PegramSeminars in Oncology|July 26, 2002
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factorMark D Pegram, David M ReeseClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2015
"Vertical" Inhibition of HER2 Yields Horizontal Gains in the ClinicGeorge W Sledge, Mark D PegramInvestigational New Drugs|September 1, 2005
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancerChristina H Yeon, Mark D PegramOncology (Williston Park, N.Y.)|February 3, 2005
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpressionGottfried E Konecny, Mark D PegramExpert Opinion on Biological Therapy|August 1, 2019
Induced pluripotent stem cells as a novel cancer vaccineLin Wang, Mark D Pegram, Joseph C WuBreast Care (Basel, Switzerland)|September 18, 2010
Targeted Therapy in Metastatic Breast Cancer: The HER2/neu OncogeneNadia Harbeck, Mark D Pegram, Josef Rüschoff, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2026
Beyond amplification: precision approaches to targeting HER2Maxwell R Lloyd, Mark D Pegram, Seth A WanderClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2019
HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid TumorsMark D Pegram, David Miles, C Kimberly Tsui, et al.Breast Cancer Research and Treatment|June 24, 2011
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysisNehmat Houssami, Petra Macaskill, Rosemary L Balleine, et al.Pageof 6